On Monday, the drug maker Novartis announced that its drug to treat chronic obstructive pulmonary disease has been approved in the European countries. During clinical trials it has been found that the drug is capable of treating the chronic obstructive pulmonary disease or smoker’s cough within four hours of administering.

The Novartis has informed that the drug will become available for clinical usage by the end of this year. The drug called Seebri Breezhaler can bring revolution in trigging smoke related health problems. It is estimated that the drug will be able to make revenue of $500 million.

The drug had been in new since June 2012. However, it has received the final approval just now. It is claimed that the drug can improve the lung function. Besides, if the drug is administered for a period of 52 weeks, it can improve the quality of life.

On 28th of September, the drug has also got approval in Japan. Just 44 mcg dose of the drug on daily basis can help one in recovering from chronic obstructive pulmonary disease. It is hoped that the introduction of the drug will help in improving the quality of life of the people.